Watershed Asset Management L.L.C. Has $280,000 Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Watershed Asset Management L.L.C. lifted its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 9.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,275 shares of the biotechnology company’s stock after purchasing an additional 108 shares during the period. Watershed Asset Management L.L.C.’s holdings in United Therapeutics were worth $280,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of UTHR. GAMMA Investing LLC acquired a new position in shares of United Therapeutics during the 4th quarter worth about $43,000. C M Bidwell & Associates Ltd. acquired a new position in United Therapeutics in the 3rd quarter valued at about $91,000. Ronald Blue Trust Inc. grew its stake in United Therapeutics by 155.9% in the 3rd quarter. Ronald Blue Trust Inc. now owns 458 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 279 shares during the last quarter. Blue Trust Inc. grew its stake in United Therapeutics by 10.0% in the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 46 shares during the last quarter. Finally, CWM LLC grew its stake in United Therapeutics by 45.7% in the 4th quarter. CWM LLC now owns 670 shares of the biotechnology company’s stock valued at $147,000 after buying an additional 210 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 11th. Wells Fargo & Company upped their price target on shares of United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research note on Thursday, March 7th. Wedbush reiterated an “outperform” rating and issued a $308.00 price target on shares of United Therapeutics in a research note on Thursday, February 22nd. SVB Leerink began coverage on shares of United Therapeutics in a research report on Monday, February 5th. They set an “outperform” rating and a $330.00 target price on the stock. Finally, Leerink Partnrs restated an “outperform” rating on shares of United Therapeutics in a research report on Monday, February 5th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $294.25.

Insider Transactions at United Therapeutics

In related news, Director Christopher Patusky sold 1,680 shares of the stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $224.00, for a total value of $376,320.00. Following the completion of the transaction, the director now owns 4 shares of the company’s stock, valued at approximately $896. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CEO Martine A. Rothblatt sold 15,000 shares of the stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $236.59, for a total value of $3,548,850.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $30,756.70. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Christopher Patusky sold 1,680 shares of the stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $224.00, for a total transaction of $376,320.00. Following the completion of the transaction, the director now directly owns 4 shares of the company’s stock, valued at approximately $896. The disclosure for this sale can be found here. In the last 90 days, insiders sold 133,390 shares of company stock valued at $31,379,925. Company insiders own 12.50% of the company’s stock.

United Therapeutics Price Performance

Shares of United Therapeutics stock traded up $0.41 on Tuesday, reaching $234.47. 521,396 shares of the stock were exchanged, compared to its average volume of 435,510. The firm’s 50 day moving average is $232.48 and its 200-day moving average is $228.69. United Therapeutics Co. has a one year low of $204.44 and a one year high of $261.54. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.28 and a current ratio of 4.41. The firm has a market cap of $11.03 billion, a PE ratio of 11.82 and a beta of 0.52.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The company had revenue of $614.70 million during the quarter, compared to the consensus estimate of $575.01 million. During the same quarter in the prior year, the firm posted $2.67 EPS. The firm’s quarterly revenue was up 25.1% on a year-over-year basis. As a group, analysts anticipate that United Therapeutics Co. will post 23.45 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.